Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001104659-20-092811
Filing Date
2020-08-10
Accepted
2020-08-10 16:55:58
Documents
15
Period of Report
2020-05-27
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K/A tm2026626d1_8ka.htm   iXBRL 8-K/A 31789
2 EXHIBIT 23.1 tm2026626d1_ex23-1.htm EX-23.1 1953
3 EXHIBIT 99.1 tm2026626d1_ex99-1.htm EX-99.1 230841
4 EXHIBIT 99.2 tm2026626d1_ex99-2.htm EX-99.2 164697
  Complete submission text file 0001104659-20-092811.txt   640158

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA nvax-20200527.xsd EX-101.SCH 3183
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nvax-20200527_lab.xml EX-101.LAB 34591
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nvax-20200527_pre.xml EX-101.PRE 22708
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2026626d1_8ka_htm.xml XML 3487
Mailing Address 21 FIRSTFIELD ROAD GAITHERSBURG MD 20878
Business Address 21 FIRSTFIELD ROAD GAITHERSBURG MD 20878 240-268-2000
NOVAVAX INC (Filer) CIK: 0001000694 (see all company filings)

EIN.: 222816046 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 000-26770 | Film No.: 201090120
SIC: 2836 Biological Products, (No Diagnostic Substances)